Propel Bio Management, LLC
- SEC CIK
- 0001969764
- Latest filing
- Aug 13, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 12, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 24
- −4 vs. Q1 2024
- Portfolio value
- $154.2M
- −$17.6M (−10.3%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APLTApplied Therapeutics, Inc. | COM | 6,567,858 | $30.7M | 19.9% | +455,952+7.5% | Added | History |
| PAGPPlains GP Holdings LP | LTD PARTNR INT A | 1,372,360 | $25.8M | 16.8% | +1,372,360 | New | History |
| TCRXTScan Therapeutics, Inc. | COM | 2,087,139 | $12.2M | 7.9% | 00.0% | Unchanged | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 43,032 | $12.1M | 7.8% | 00.0% | Unchanged | History |
| ACHVAchieve Life Sciences, Inc. | COM | 2,453,092 | $11.5M | 7.5% | 00.0% | Unchanged | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 869,927 | $8.96M | 5.8% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 327,752 | $7.69M | 5.0% | 00.0% | Unchanged | History |
| Avidity Biosciences, Inc.05370A108 | COM | 178,500 | $7.29M | 4.7% | 00.0% | Unchanged | – |
| ARDXArdelyx, Inc. | COM | 924,583 | $6.85M | 4.4% | +330,409+55.6% | Added | History |
| ABEOAbeona Therapeutics Inc. | COM NEW | 1,248,044 | $5.29M | 3.4% | +1,248,044 | New | History |
| FULCFulcrum Therapeutics, Inc. | COM | 750,000 | $4.65M | 3.0% | 00.0% | Unchanged | History |
| LONALeonaBio, Inc. | COM | 1,492,792 | $3.96M | 2.6% | 00.0% | Unchanged | History |
| TSATTelesat Corp | CL A & CL B SHS | 365,781 | $3.33M | 2.2% | +75,000+25.8% | Added | History |
| VRCAVerrica Pharmaceuticals Inc. | COM | 424,937 | $3.10M | 2.0% | +424,937 | New | History |
| KURAKura Oncology, Inc. | COM | 130,000 | $2.68M | 1.7% | 00.0% | Unchanged | History |
| EIGREiger BioPharmaceuticals, Inc. | COM NEW | 146,381 | $1.85M | 1.2% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 83,259 | $1.71M | 1.1% | 00.0% | Unchanged | History |
| KYMRKymera Therapeutics, Inc. | COM | 56,359 | $1.68M | 1.1% | 00.0% | Unchanged | History |
| KYNKayne Anderson Energy Infrastructure Fund, Inc. | COM | 147,033 | $1.52M | 1.0% | 00.0% | Unchanged | History |
| TRVITrevi Therapeutics, Inc. | COM | 260,000 | $774.8K | 0.5% | 00.0% | Unchanged | History |
| Fidelity Inv Mmtrsy 1 680X9USDFIDT | COMM | 317,014 | $317.0K | 0.2% | +105,473+49.9% | Added | – |
| Cybin Ord23256X100 | COM | 850,000 | $230.3K | 0.1% | 00.0% | Unchanged | – |
| Maat Pharma Saca00BNRR5C1 | COMM | 1,362 | $9.75K | <0.1% | +1,362 | New | – |
| Contra Chinook Therapeu169CVR016 | COM | 79,357 | $9.75K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q1 2024 (8)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| Simplify Exchange Traded Fun82889N632 | ENHANCED INM ETF | 1,492,581 | $28.0M | 16.3% | – |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 270,664 | $4.47M | 2.6% | History |
| iShares Tr464288588 | MBS ETF | 22,400 | $2.07M | 1.2% | – |
| MIRMMirum Pharmaceuticals, Inc. | COM | 70,000 | $1.76M | 1.0% | History |
| MRNSMarinus Pharmaceuticals, Inc. | COM NEW | 180,100 | $1.63M | 0.9% | History |
| STROSutro Biopharma, Inc. | COM | 195,000 | $1.10M | 0.6% | History |
| XFORX4 Pharmaceuticals, Inc | COM | 535,000 | $743.6K | 0.4% | History |
| iShares Iboxx $ Investment Grade Corporate Bond ETF464287242 | ETF | 4,456 | $485.3K | 0.3% | – |